Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
RESEARCH TOOLSreports
Holding EYPT?
Track your performance easily
EYPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.90 - $30.99
Previous Close$7.1
Volume4.16M
Average Volume (3M)920.87K
Market Cap
$484.58M
Enterprise Value$252.71M
Total Cash (Recent Filing)$253.79M
Total Debt (Recent Filing)$21.92M
Price to Earnings (P/E)―
Beta2.94
Next Earnings
Feb 27, 2025EPS Estimate
-$0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding68,251,031
10 Day Avg. Volume1,133,187
30 Day Avg. Volume920,867
Standard Deviation0.45
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)2.22
Price to Sales (P/S)10.60
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.39
Enterprise Value/Gross Profit6.11
Enterprise Value/Ebitda-2.50
Forecast
1Y Price Target
$28.83Price Target Upside306.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EyePoint Pharmaceuticals News
PremiumCompany Announcements
EyePoint Pharmaceuticals Advances in Retinal Therapeutics
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first patient was dosed in the pivotal LUCIA trial of DURAVYU in wet AMD, signaling progress in the development of a promising treatment.
Market OpportunityWith approximately 1 million patients in the US, diabetic macular edema represents a significant opportunity for EyePoint.
Safety ProfileThere were no DURAVYU-related ocular or systemic serious adverse events, highlighting the potential safety of the treatment.
Bears Say
Clinical TrialsRisks include the possibility of EYP-1901 failing in clinical trials or not obtaining regulatory approval.
Competitive ChallengesThe path forward for CLS-AX is seen as potentially challenging both clinically and commercially, reinforcing the competitive edge for EYPT.
ValuationPotential dilution risk is a concern for the valuation of the company.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $6.90 and its highest was $30.99 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Feb 27, 2025 which is in 66 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Nov 07, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.006.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -$0.5.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 68,251,030 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went down -4.056%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Among the largest hedge funds holding EyePoint Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds EyePoint Pharmaceuticals Inc’s shares valued at 8M.
---
EyePoint Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.83 (306.06% Upside)
$28.83 (306.06% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 321.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.32%
12-Months-Change
Fundamentals
Return on Equity
-74.68%
Trailing 12-Months
Asset Growth
88.02%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
---
EYPT Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in financial strength, strategic transformation, and positive clinical trial results. The main challenge noted was a decrease in net product revenue due to exiting the commercial business, but this was part of a strategic shift. Overall, the sentiment is positive as the company is well-capitalized and on track with its clinical and strategic goals.Read More>---
EYPT Stock 12 Month Forecast
Average Price Target
$28.83
▲(306.06% Upside)
Technical Analysis
Best Analysts Covering EYPT
1 Year
1 Year Success Rate
9/23 ratings generated profit
1 Year Average Return
+49.53%
reiterated a buy rating 18 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 39.13% of your transactions generating a profit, with an average return of +49.53% per trade.
---